Emergency Resuscitative Endovascular Balloon Occlusion of the Aorta in Out of Hospital Cardiac Arrest
Launched by QUEEN MARY UNIVERSITY OF LONDON · Oct 4, 2023
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying a procedure called Resuscitative Endovascular Balloon Occlusion of the Aorta (REBOA) to see if it can help patients who experience cardiac arrest outside of the hospital. The goal is to find out if this procedure can be safely performed by emergency medical teams and if it can improve the chances of survival for patients who have stopped breathing or whose hearts have stopped beating due to non-traumatic causes, such as heart problems.
To be eligible for the trial, participants need to be between 18 and 80 years old, live in the East of England, and have experienced a cardiac arrest without any CPR for less than 10 minutes. The study specifically focuses on patients who are still in cardiac arrest when the emergency team arrives. Those with severe health issues, known terminal illnesses, or who are pregnant will not be included. If chosen to participate, you can expect emergency responders to provide conventional life support as well as the additional REBOA procedure, which could help improve blood flow during resuscitation efforts.
Gender
ALL
Eligibility criteria
- • Inclusion criteria
- • Non-Traumatic OHCA in patients within the East of England area AND with a East Anglian Air Ambulance (EAAA) REBOA team in attendance
- • Patients below or equal to 80yrs of age and above or equal to 18yrs of age, according to available information/estimate at scene
- • No flow \<10 mins from data available (i.e. total period in OHCA with no CPR)
- • In cardiac arrest (with no sustained ROSC) on arrival of the EAAA REBOA team
- • Exclusion criteria
- • Patients aged less than 18 or above 80 years
- • Known terminal illness
- • Multiple severe co-morbidities
- • Traumatic Cardiac Arrest (TCA)
- • Inability to deploy mechanical CPR (e.g. LUCAS Device)
- • Pregnancy, obvious or suspected
About Queen Mary University Of London
Queen Mary University of London is a prestigious research-intensive institution recognized for its commitment to advancing medical science and improving health outcomes. As a leading sponsor of clinical trials, the university harnesses its academic excellence and innovative research capabilities to explore groundbreaking treatments and therapies across various medical disciplines. With a focus on collaboration, the institution engages with a diverse network of clinicians, researchers, and industry partners to ensure rigorous study design, ethical conduct, and the translation of research findings into clinical practice. Queen Mary University of London is dedicated to contributing to the global body of knowledge in healthcare through high-quality clinical research that prioritizes patient safety and welfare.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Norwich, , United Kingdom
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported